

Supplemental information

MLL-rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-binding Protein, Galectin-1

Running title: Galectin-1 overexpression in MLL ALL

Przemyslaw Juszczynski^{1,8}, Scott J. Rodig^{2,8}, Jing Ouyang¹, Evan O'Donnell¹, Kunihiro Takeyama¹, Wojciech Mlynarski³, Katarzyna Mycko³, Tomasz Szczepanski⁴, Anna Gaworczyk⁵, Andrei Krivtsov⁶, Joerg Faber⁶, Amit U. Sinha⁶, Gabriel A. Rabinovich⁷, Scott A. Armstrong⁶, Jeffery L. Kutok² and Margaret A. Shipp¹

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; ² Department of Pathology, Brigham & Women's Hospital, Boston, MA; ³ Department of Pediatrics, Hematology, Oncology & Diabetology, Medical University of Lodz, Poland; ⁴ Department of Pediatric Hematology and Oncology, Medical University of Silesia, Zabrze, Poland; ⁵ Department of Pediatric Hematology and Oncology, Medical University of Lublin, Poland; ⁶ Department of Pediatric Oncology, Children's Hospital, Boston, MA; ⁷ Laboratory of Immunopathology, Institute of Biology and Experimental Medicine, CONICET, Buenos Aires, Argentina; ⁸ These authors contributed equally

Corresponding authors: Jeffery L. Kutok , Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115 phone 617-732-5714, Fax 617-264-5169, e-mail jkutok@partners.org; Margaret A. Shipp, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, phone 617-632-3874, Fax 617-632-4734, e-mail margaret_shipp@dfci.harvard.edu

Expression of Gal-1 in two independent series of transcriptionally profiled primary B-ALLs with known MLL translocation status (Armstrong et al, 2002, Nat Genet. 2002; 30: 41-47; Yeoh et al, Cancer Cell. 2002; 1: 133-143)

